IDEXX LABORATORIES INC /DE IDXX
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
8/9
Piotroski F — financial health
10.43
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $4.3B | $1.1B | $2.7B | $1.1B | $1.6B |
| 2024 | $3.9B | $887.9M | $2.4B | $808.1M | $1.6B |
| 2023 | $3.7B | $845.0M | $2.2B | $772.9M | $1.5B |
| 2022 | $3.4B | $679.1M | $2.0B | $394.1M | $608.7M |
| 2021 | $3.2B | $744.8M | $1.9B | $636.0M | $690.0M |
| 2020 | $2.7B | $581.8M | $1.6B | $541.1M | $632.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| FENNELL GEORGE | Executive Vice President | 2026-06-01 | Option exercise | 639 | — |
| FENNELL GEORGE | Executive Vice President | 2026-06-01 | Tax withheld | 284 | $566.79 |
Why these scores methodology →
Piotroski F-score: 8/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 10.43 (safe)
- Working capital / assets 0.079
- Retained earnings / assets 1.908
- EBIT / assets 0.406
- Equity / liabilities 0.92
Source: SEC EDGAR filings · CIK 0000874716 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.